Trials / Active Not Recruiting
Active Not RecruitingNCT06061718
Travoprost Intraocular Implant in Conjunction With Cataract Surgery
Multicenter, Open-label, Single-arm Trial to Evaluate the Safety and Efficacy of iDose® TR (Travoprost Intraocular Implant) in Conjunction With Cataract Surgery
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Glaukos Corporation · Industry
- Sex
- All
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
Subjects with cataract requiring extraction and who have open-angle glaucoma or ocular hypertension will undergo screening and washout from IOP-lowering medication, if applicable. Eligible subjects who meet all inclusion criteria and none of the exclusion criteria and who undergo successful cataract extraction with implantation of a posterior chamber intraocular lens (PC-IOL) will receive a travoprost intraocular implant and followed up for 12 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | iDose TR | anchored intracameral implant containing travoprost |
Timeline
- Start date
- 2023-09-11
- Primary completion
- 2024-03-18
- Completion
- 2024-12-20
- First posted
- 2023-09-29
- Last updated
- 2024-06-03
Locations
1 site across 1 country: Armenia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06061718. Inclusion in this directory is not an endorsement.